Misconduct Apology

A neurodegenerative disease researcher found guilty of fabricating results in funding applications has written an open letter of apology and clarification.

Written byDan Cossins
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, STEAKPINBALLLast month Paul Muchowksi, a senior researcher at the Gladstone Institute for Neurological Disease, was reprimanded after the Office of Research Integrity (ORI) found that he had reported data that didn’t exist at the time he submitted three grant applications to the National Institutes of Health, one of which was funded. Now, Murchowski has written an open letter of apology and clarification, posted last week (January 9) at Retraction Watch.

In the letter, Murchowski expressed “sincere remorse and apologies” to the scientific community. “In these instances, I stated that the experiments had, in fact, been performed prior to their completion,” he wrote. “Based on previous experience with such experiments, I believed that I could perform these experiments by the time that my grant would be reviewed.” He claimed that the studies in question were not critical in determining the fate of the applications, but wrote that, “I now know with conviction and remorse to only include the data I have at hand and have checked myself.”

Murchowski added that his published findings have never been called into question, that there will be no retractions based on the ORI’s findings, and that the funded grant at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies